BACKGROUND: β-Synuclein is an emerging synaptic blood biomarker for Alzheimer ́s disease (AD) and correlates with cognitive impairment, brain atrophy and amyloid/tau pathology. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.